Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 전대원 | - |
dc.date.accessioned | 2021-02-16T00:29:31Z | - |
dc.date.available | 2021-02-16T00:29:31Z | - |
dc.date.issued | 2019-12 | - |
dc.identifier.citation | CLINICAL INFECTIOUS DISEASES, v. 71, no. 11, page. 2840-2848 | en_US |
dc.identifier.issn | 1537-6591 | - |
dc.identifier.issn | 1058-4838 | - |
dc.identifier.uri | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciz1160/5645107 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/158234 | - |
dc.description.abstract | Background Cure rates of hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) for patients with active and inactive hepatocellular carcinoma (HCC) may differ, but well-controlled studies are limited. We aimed to evaluate DAA outcomes in a large East Asian HCV/HCC population compared with HCV/non-HCC patients. Methods Using data from the Real-World Evidence from the Asia Liver Consortium (REAL-C) registry (Hong Kong, Japan, South Korea, and Taiwan), we used propensity score matching (PSM) to match HCC and non-HCC (1:1) groups for age, sex, cirrhosis, prior treatment, HCV genotype, treatment regimen, baseline platelet count, HCV RNA, total bilirubin, alanine aminotransferase, and albumin levels to evaluate DAA treatment outcomes in a large population of HCV/HCC compared with HCV/non-HCC patients. Results We included 6081 patients (HCC, n = 465; non-HCC, n = 5 616) treated with interferon-free DAAs. PSM of the entire study population yielded 436 matched pairs with similar baseline characteristics. There was no statistically significant difference in the overall SVR rate of HCC (92.7%) and non-HCC (95.0%) groups. Rates of treatment discontinuation, adverse effects, and death were also similar between HCC and non-HCC groups. Among patients with HCC, those with active HCC had a lower SVR than inactive HCC cases (85.5% vs 93.7%; P = .03). On multivariable analysis, active HCC, but not inactive HCC, was significantly associated with lower SVR (OR, 0.28; P = .01) when compared with non-HCC. Conclusions Active HCC but not inactive HCC was independently associated with lower SVR compared with non-HCC patients undergoing DAA therapy, although cure rate was still relatively high (85%) in active HCC patients. | en_US |
dc.description.sponsorship | This work was supported by an investigator-initiated research grant from Gilead Sciences to Stanford University. The authors independently collected data, designed and performed all study analyses, and drafted the manuscript. | en_US |
dc.language.iso | en | en_US |
dc.publisher | OXFORD UNIV PRESS INC | en_US |
dc.subject | hepatitis C virus | en_US |
dc.subject | hepatocellular carcinoma | en_US |
dc.subject | direct-acting antivirals | en_US |
dc.subject | Asian | en_US |
dc.subject | propensity score matching | en_US |
dc.title | Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1093/cid/ciz1160 | - |
dc.relation.page | 1-38 | - |
dc.relation.journal | CLINICAL INFECTIOUS DISEASES | - |
dc.contributor.googleauthor | Ogawa, Eiichi | - |
dc.contributor.googleauthor | Toyoda, Hidenori | - |
dc.contributor.googleauthor | Iio, Etsuko | - |
dc.contributor.googleauthor | Jun, Dae Won | - |
dc.contributor.googleauthor | Huang, Chung-Feng | - |
dc.contributor.googleauthor | Enomoto, Masaru | - |
dc.contributor.googleauthor | Hsu, Yao-Chun | - |
dc.contributor.googleauthor | Haga, Hiroaki | - |
dc.contributor.googleauthor | Iwane, Shinji | - |
dc.contributor.googleauthor | Wong, Grace | - |
dc.relation.code | 2019002630 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | noshin | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.